Cited by 97Psychotherapy Techniques and ApplicationsAnxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesTreatment of Major Depression

Divergent outcomes in cognitive-behavioral therapy and pharmacotherapy for adult depression

Open access
Vittengl, Jeffrey R., Jarrett, Robin B., Weitz, Erica, Hollon, Steven D., Twisk, Jos, Cristea, Ioana, David, Daniel, DeRubeis, Robert J. +14 more·2016·American Journal of Psychiatry

Abstract

OBJECTIVE: Although the average depressed patient benefits moderately from cognitive-behavioral therapy (CBT) or pharmacotherapy, some experience divergent outcomes. The authors tested frequencies, predictors, and moderators of negative and unusually positive outcomes. METHOD: Sixteen randomized clinical trials comparing CBT and pharmacotherapy for unipolar depression in 1,700 patients provided individual pre- and posttreatment scores on the Hamilton Depression Rating Scale (HAM-D) and/or Beck Depression Inventory (BDI). The authors examined demographic and clinical predictors and treatment moderators of any deterioration (increase ≥1 HAM-D or BDI point), reliable deterioration (increase ≥8 HAM-D or ≥9 BDI points), extreme nonresponse (posttreatment HAM-D score ≥21 or BDI score ≥31), superior improvement (HAM-D or BDI decrease ≥95%), and superior response (posttreatment HAM-D or BDI score of 0) using multilevel models. RESULTS: About 5%-7% of patients showed any deterioration, 1% reliable deterioration, 4%-5% extreme nonresponse, 6%-10% superior improvement, and 4%-5% superior response. Superior improvement on the HAM-D only (odds ratio=1.67) and attrition (odds ratio=1.67) were more frequent in pharmacotherapy than in CBT. Patients with deterioration or superior response had lower pretreatment symptom levels, whereas patients with extreme nonresponse or superior improvement had higher levels. CONCLUSIONS: Deterioration and extreme nonresponse and, similarly, superior improvement and superior response, both occur infrequently in randomized clinical trials comparing CBT and pharmacotherapy for depression. Pretreatment symptom levels help forecast negative and unusually positive outcomes but do not guide selection of CBT versus pharmacotherapy. Pharmacotherapy may produce clinician-rated superior improvement and attrition more frequently than does CBT.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1176/appi.ajp.2015.15040492

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [32]Weitz E Hollon SD Twisk J van Straten A David D Cuijpers P Does baseline depression severity moderate outcomes between CBT and pharmacotherapy? An individual participant data meta-analysis In press JAMA Psychiatry

Cited by

Sorted by citations

Authors
Vittengl, J. R., Jarrett, R. B., Weitz, E., Hollon, S. D., Twisk, J., Cristea, I., David, D., DeRubeis, R. J., Dimidjian, S., Dunlop, B. W., Faramarzi, M., Hegerl, U., Kennedy, S. H., Kheirkhah, F., Mergl, R., Miranda, J., Mohr, D. C., Rush, A. J., Segal, Z. V., Siddique, J., Simons, A. D., & Cuijpers, P.
Affiliations
Truman State University (US)
Venue
American Journal of Psychiatry
Published
2016-05-01
Volume
173
Issue
5
Pages
481-490
ISSN
  • 0002-953X (ISSN-L)
  • 1535-7228
OpenAlex
W2252762384
Cited by
97
References
42
Citations by year
2026: 2 · 2025: 5 · 2024: 4 · 2023: 4 · 2022: 7 · 2021: 47 · 2020: 6 · 2019: 9 · 2018: 5 · 2017: 4 · 2016: 4
FWCI
1.09
Type
journal article
Language
en
Open access
Locations
  • American Journal of Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • Padua Research Archive (University of Padova) (submittedVersion)
Funders
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • GlaxoSmithKline
  • Vanderbilt University
  • University of Pennsylvania
  • Emory University
  • Northwestern University
  • University of Texas Southwestern Medical Center
  • University of Notre Dame
  • Pennsylvania State University
  • Fondation Brain Canada
  • Montana State University
  • Truman State University
  • Universität Trier
  • European Commission
  • National University of Singapore
  • ZonMw
  • Vrije Universiteit Amsterdam
  • Fonds NutsOhra
  • University of Toronto
  • Babol University of Medical Sciences
  • Servier
  • H. Lundbeck A/S
  • National Institutes of Health
  • St. Jude Medical
  • University of California, Los Angeles
  • School of Medicine, Emory University
  • Feinberg School of Medicine
  • Canadian Institutes of Health Research
  • National Institute of Mental Health (P20MH090318, R01MH100482, R01MH060713, R34MH095907, R01MH095753, R01MH060998, K02MH001697, MH 01697)
  • National Institute on Drug Abuse
Topics
  • Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
Keywords
cognitive behavioral therapy, pharmacotherapy, adult depression, major depressive disorder, treatment outcome variability, treatment response, treatment deterioration, attrition, predictors of treatment outcome, moderators of treatment outcome
MeSH terms
Adult, Antidepressive Agents, Major Depressive Disorder, Depressive Disorder, Female, Humans, Male, Psychiatric Status Rating Scales, Cognitive Behavioral Therapy, Randomized Controlled Trials as Topic, Treatment Outcome, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review